119 results about "Venlafaxine" patented technology

According to the invention, there is provided a phosphate derivative of a compound having a secondary hydroxy group. The compound having a secondary hydroxyl group may, for example, be chosen from pravastatin, atorvastatin venlafaxine, their derivatives and mixtures thereof.

The invention discloses a venlafaxine hydrochloride sustained-release tablet preparation which comprises venlafaxine hydrochloride, framework material, diluent, lubricant, adhesive and coating material. The experiments demonstrate that the venlafaxine hydrochloride sustained-release tablet achieves better sustained-release effect, can reduce the dosing frequency and is convenient for the patients to use. The invention also provides a preparation method thereof.

In certain embodiments, the present invention is directed to a controlled release oral solid dosage form comprising a matrix comprising a therapeutically effective amount of venlafaxine, an active metabolite of venlafaxine, or a pharmaceutically acceptable salt thereof, dispersed in a cross-linked gelling agent, the matrix providing a controlled release of venlafaxine, active metabolite of venlafaxine, or salt thereof to provide 24 hour therapeutic plasma levels after oral administration to human patients.

The invention provides a delayed burst release formulation comprising a core formed as a compressed tablet and an outer coating that surrounds the core; said core comprising venlafaxine, or a pharmaceutically acceptable salt thereof, at least one burst controlling agent and a disintegrant; and said outer coating comprising a water insoluble hydrophobic carrier and water-insoluble but hydrophilic particulate matter.

The invention discloses a process for preparing hexahydrophenol derivative for making the intermediate of venlafaxime, a novel antidepressant drug, comprising the steps of, choosing suitable dissolvent and reaction condition, by the action of initiation nitriles or polyamides compounds having general formula (3) with alkali metal chloride hydrogenated or organic lithium derivatives, compound having general formula (2) can be obtained, under suitable dissolvent and reaction conditions, compounds having general formula (2) can be transformed into compounds having general formula (1) through aluminium-hydrogen compounds reduction or catalytic hydrogenation with nickel presence. The product is antidepressant drug with proven curative effects.

The invention discloses a venlafaxine sustained-release capsule and a preparation process thereof. Ethyl cellulose and enteric acrylic acid resin are compounded as an adhesive; an isolation layer is coated outside a blank pellet, so that the pellet is not released at all, the osmotic pressure inside a sustained-release pellet is reduced, and the release speed of the medicine is decelerated; and meanwhile the adhesive is used for a medicine-containing layer and a sustained-release protection layer, so that venlafaxine medicine layers are encapsulated in a sustained-release material, the dissolubility of the pellet is further reduced, and the stable release of the medicine is guaranteed to reach a standard requirement.

A sustained release Venlafaxine composition that includes a plurality of non-agglomerated, uniformly-shaped and sized microbeads of inert core particles having a first coating layer. The first coating layer includes an active agent of Venlafaxine or a pharmaceutical acceptable salt thereof, a binder, and an anti-tack agent. The active agent is present in the first coating layer in a concentration of at least about 5% to about 70% by weight of the composition, the binder is present in an amount of at least 35% by weight of the active agent, or in a further layer located upon or below the first coating layer, or as an alternating layer between plural first layers, wherein the binder is present in an amount of less than about 2.5% by weight of the composition, and the anti-tack agent is present in the first coating layer in a concentration of about 2.5% to about 20% by weight based on the weight of the active agent. The composition is also substantially free of organic acid.

The invention belongs to the field of pharmaceutical preparations, and discloses a venlafaxine hydrochloride sustained release capsule and a preparation method thereof. The content of the sustained release capsule is a sustained release micro pill, wherein the sustained release pill is successively provided with a pill core, an isolating layer and a sustained release layer from the interior to the exterior, the pill core is prepared from the following constituents according to weight percentage composition: 45-48% of venlafaxine hydrochloride, 15-18% of bulking agent, 3-3.5% of disintegrating agent, 4-6% of povidone K 30, 24-26% of absolute ethyl alcohol and the balance being water; the isolating layer is prepared from the following constituents according to weight percentage composition: 11-13% povidone K30, 83-86% of absolute ethyl alcohol and the balance being talcum powder; the sustained release layer is prepared from the following constituents according to weight percentage composition: 38-42% of ethocel suspension, 0.1-1.0% of polyethylene glycol-60000 and the balance being water, wherein the ethocel accounts for 20-30% of the ethocel suspension in mass; and the preparation method provided by the invention has the following steps of preparing the pill core, packing the isolating layer, packing the sustained release layer and filling a capsule, thus obtaining the sustained release capsule. The venlafaxine hydrochloride sustained release capsule provided by the invention adopts the ethocel, the flammability is low, the hygroscopicity is small, good film formation property can be achieved, the material is stable and is easy to control, and the venlafaxine hydrochloride sustained release capsule is safe and environment-friendly.

The invention relates to a venlafaxine hydrochloride slow-release capsule and a preparation method thereof. A drug-containing core of the slow-release capsule comprises venlafaxine hydrochloride, microcrystalline cellulose, gas phase silica, Tween-80, and hydroxypropyl methylcellulose; a slow-release coating comprises polyacrylic resin, talcum powder, polyethylene glycol and lauryl sodium sulfate. The invention realizes a pure water system for the capsule production by the addition of gas phase silica to change material flowing, and the selection of slow-release coating. The venlafaxine hydrochloride slow-release capsule prepared by the system is stable in drug release, has effective continuous release time of 24 hours, and is taken only once a day. The method is simple in process, mild in condition, free of any organic solvent, low in equipment requirements, and suitable for industrial production.

The invention belongs to the technical field of drug detection, and particularly relates to a method and a kit for detecting 19 drugs and metabolites thereof in blood through liquid chromatography-tandem mass spectrometry. The substances to be detected comprise sulpiride, pentafluridol, mianserin, buspirone, tandospirone, hydroxyazine, diazepam, venlafaxine, moclobemide, imipramine, paroxetine, reboxetine, amitriptyline, sertraline, digoxin, clonazepam, clopidogrel, toluenesulfobutyl urea, glimepiride, 1-pyrimidinepiperazine, desmethylvenlafaxine, 6-hydroxy buspirone and normipramine, and the substances to be detected are selected from the group consisting of sulpiride, pentafluridol, mianserin, venlafaxine, metandospirone, metandospirone, hydroxazine, diazepam, venlafaxine, moclobemide, the pharmaceutical composition is prepared from noramitriptyline, nordiazepam and clopidogrel metabolite; the detection method comprises the following steps: calibrating a standard solution, treating a to-be-detected sample, and detecting the to-be-detected sample by adopting high performance liquid chromatography-mass spectrometry. The embodiment of the invention can quickly and accurately measure the content, and the sample treatment method is simple and easy to implement, high in sensitivity and accurate in quantification.